D37d20b-1bf7-4432-b26f-eaa223629580 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 01)
Glipizide And Metformin Hcl
Product Images NDC 50090-1082
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Glipizide And Metformin Hcl (NDC 50090-1082). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fd6f18e-67ad-4662-9a9c-04758aa16464 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 02)
Table 1 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 03)
This is a table of Metformin Dose and Renal Clearance rates for different subject groups, including healthy adults, adults with type 2 diabetes, elderly adults, and renal-impaired adults. The table provides information on the number of subjects, peak plasma concentration, time to peak plasma concentration, and renal clearance rates for different Metformin doses. The results suggest that Metformin has varied effects on different subject groups, with noticeable differences in peak plasma concentration and renal clearance rates. This information can be useful for healthcare professionals in determining appropriate Metformin doses for patients based on their age, health status, and renal function.*
Table 2 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 04)
This is a table showing various medications and dosages used in a study. The study included Glipizide and Metformin HCI at different dosage levels. The table displays the mean final dose, Hemoglobin A levels, and Fasting Plasma Glucose levels among others for each medication type and dosage level. The study indicates the percentage of patients with final Hemoglobin A levels of less than 7% and the difference from Glipizide and Metformin HCI at specific dosage levels. The results of the study are significant with p<0.001.*
Table 3 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 05)
This is a medication table showing the dosage and effectiveness of Glipizide and Metformin HCI 5. The table shows the mean final dose, Hemoglobin A levels, and the percentage of patients with the final HbA levels less than 7%, as well as the fasting plasma glucose levels. The medication dosage is given in tablets of 5 mg for Glipizide and 500 mg for Metformin HCI, and the mean final dose varies. The difference in effectiveness is also shown compared to Glipizide and Metformin alone. The text is useful for medical professionals evaluating the effectiveness of Glipizide and Metformin HCI 5 for treating diabetes.*
Table 4 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 06)
The text provides a table of adverse events experienced by patients taking different medication combinations of glipizide and metformin HCI. The table includes the number of patients in each group and the percentage of patients that experienced each adverse event. Adverse events listed include upper respiratory infection, diarrhea, dizziness, hypertension, and nausea/vomiting.*
Table 5 (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 07)
This is a table showing the number and percentage of patients (N=84 or N<75) who experienced adverse events such as diarrhea, headache, upper respiratory infection, musculoskeletal pain, nausea/vomiting, abdominal pain, and UTI when taking Glipizide 5mg, Metformin 500mg, or Glipizide and Metformin HCI tablets. The dose of Glipizide was fixed at 30mg daily while the doses of Metformin and Glipizide and Metformin HCI tablets were titrated.*
Logo (Ee5fdf68 Df2d 4965 8224 2c2df30f2f22 10)
Label Image (Lbl500901082)
Product no is "Ehizoe we 5893-0" and it contains 180 tablets. It should be stored at -7 degrees Celsius.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
